{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:57:46Z","timestamp":1792684666847,"version":"4.5.0"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","internationaljournalofcardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.ijcard.2024.131855","type":"journal-article","created":{"date-parts":[[2024,2,13]],"date-time":"2024-02-13T03:47:50Z","timestamp":1707796070000},"page":"131855","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Cost-effectiveness of transthyretin cardiac amyloidosis screening and treatment: A Dilemma for the clinician"],"prefix":"10.1016","volume":"402","author":[{"given":"Vincenzo","family":"Castiglione","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Aimo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Vergaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2024.131855_bb0005","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1002\/ejhf.2542","article-title":"Head-to-head comparison between recommendations by the ESC and ACC\/AHA\/HFSA heart failure guidelines","volume":"24","author":"Bay\u00e9s-Gen\u00eds","year":"2022","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ijcard.2024.131855_bb0010","article-title":"Cost-effectiveness of systematic screening and treatment of transthyretin amyloid cardiomyopathy (ATTR-CM) in patients with heart failure with preserved ejection fraction (HFpEF) in United States","author":"Lau","year":"2023","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ijcard.2024.131855_bb0015","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1001\/jamacardio.2021.3070","article-title":"Prevalence of transthyretin amyloid cardiomyopathy in heart failure with preserved ejection fraction","volume":"6","author":"AbouEzzeddine","year":"2021","journal-title":"JAMA Cardiol."},{"key":"10.1016\/j.ijcard.2024.131855_bb0020","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1161\/CIRCULATIONAHA.119.045093","article-title":"Cost-effectiveness of Tafamidis therapy for transthyretin amyloid cardiomyopathy","volume":"141","author":"Kazi","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2024.131855_bb0025","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.026308","article-title":"Modeling the cost and health impacts of diagnostic strategies in patients with suspected transthyretin cardiac amyloidosis","volume":"11","author":"Ge","year":"2022","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.ijcard.2024.131855_bb0030","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1001\/jamacardio.2019.5233","article-title":"Tafamidis-a pricey therapy for a not-so-rare condition","volume":"5","author":"Gurwitz","year":"2020","journal-title":"JAMA Cardiol."},{"key":"10.1016\/j.ijcard.2024.131855_bb0035","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/suac012.281","article-title":"Redefining the epidemiology of cardiac amyloidosis. A systematic review and meta-analysis of screening studies","author":"Aimo","year":"2022","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ijcard.2024.131855_bb0040","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/ejhf.2824","article-title":"Left ventricular wall thickness and severity of cardiac disease in women and men with transthyretin amyloidosis","volume":"25","author":"Aimo","year":"2023","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ijcard.2024.131855_bb0045","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1177\/2047487319877708","article-title":"Keys to early diagnosis of cardiac amyloidosis: red flags from clinical, laboratory and imaging findings","volume":"27","author":"Vergaro","year":"2020","journal-title":"Eur. J. Prev. Cardiol."},{"key":"10.1016\/j.ijcard.2024.131855_bb0050","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/ehf2.14188","article-title":"SGLT2 inhibitor therapy for transthyretin amyloid cardiomyopathy: early tolerance and clinical response to dapagliflozin","volume":"10","author":"Dobner","year":"2023","journal-title":"ESC Heart Fail."}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527324002626?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527324002626?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T21:04:40Z","timestamp":1759093480000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527324002626"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":10,"alternative-id":["S0167527324002626"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2024.131855","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-effectiveness of transthyretin cardiac amyloidosis screening and treatment: A Dilemma for the clinician","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2024.131855","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"131855"}}